logo
Plus   Neg
Share
Email

Axel Springer's New Berlin Office Building To Be Inaugurated In 2020

German media holding company Axel Springer SE (AXELF.PK) announced Friday that its new office building in Berlin will be completed on schedule and on budget. The traditional handover of the key will be done on December 19, while the official opening and inauguration will be in 2020.

The new building, which started constructing in 2016, is located on a 10,000 square-meter plot at the site of the the former wall in the heart of the erstwhile newspaper district. It was designed by the Dutch architect Rem Koolhaas, Office for Metropolitan Architecture.

Altogether, over 52,000 square meters will be available for a total of 3,500 employees. Beginning in spring next year, Axel Springer's various units and companies will move in.

Axel Springer will celebrate the official opening of the new office building with a series of events highlighting both the history and the future of the company.

The company said the series will kick off in late February with the placement of "Stolperstein" cobblestones as part of a small ceremony in remembrance of the Berliners who were ousted from the former newspaper district, deported and in some cases murdered.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT